Real-world performance of SARS-Cov-2 serology tests in the United States, 2020.

ABSTRACT:

Background

Real-world performance of COVID-19 diagnostic tests under Emergency Use Authorization (EUA) must be assessed. We describe overall trends in the performance of serology tests in the context of real-world implementation.

Methods

Six health systems estimated the odds of seropositivity and positive percent agreement (PPA) of serology test among people with confirmed SARS-CoV-2 infection by molecular test. In each dataset, we present the odds ratio and PPA, overall and by key clinical, demographic, and practice parameters.

Results

A total of 15,615 people were observed to have at least one serology test 14-90 days after a positive molecular test for SARS-CoV-2. We observed higher PPA in Hispanic (PPA range: 79-96%) compared to non-Hispanic (60-89%) patients; in

SUBMITTER: Rodriguez-Watson CV 

PROVIDER: S-EPMC9897562 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature